Our data demonstrate the profound consequences of inhibiting both HIF-1 and HIF-2 activity in HCC tumors, with effects on tumor growth and vascularization, as well as reprogramming of the tumor immune microenvironment to favor antitumor immunity and improve the response to anti-PD1 therapy (Figure 10). Here, HIF1A is linked to hepatocellular carcinoma.